CARIBBEAN 360 – A dengue fever vaccine developed by pharmaceutical giant Sanofi has been approved for use by Mexico, marking the first approval in the world for any vaccine for the debilitating, sometimes fatal, mosquito-borne disease.
The French drug company said in a news release that the vaccine, “Dengvaxia,” was approved by Mexico’s Federal Commission for the Protection against Sanitary Risk for prevention of dengue in people 9 to 45 years old living in endemic areas.
According to Olivier Charmeil, executive vice president for vaccines at Sanofi: “We are making dengue the next vaccine-preventable disease.”
It nevertheless remains uncertain how widely the vaccine will be deployed, in Mexico and other countries, because of national budget constraints, as well as limits to its effectiveness.
In clinical trials, the vaccine reduced the risk of developing dengue by about 60 percent, which some experts have said is less effective than desired.